Marshall Wace LLP purchased a new position in shares of Enhabit, Inc. (NYSE:EHAB – Get Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 322,247 shares of the company’s stock, valued at approximately $4,526,000. Marshall Wace LLP owned about 0.65% of Enhabit at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of EHAB. Bessemer Group Inc. acquired a new stake in Enhabit during the 3rd quarter worth approximately $26,000. CI Investments Inc. purchased a new position in shares of Enhabit in the 2nd quarter valued at $27,000. Lazard Asset Management LLC acquired a new position in shares of Enhabit during the 3rd quarter valued at $34,000. IFP Advisors Inc purchased a new stake in Enhabit during the 3rd quarter worth $39,000. Finally, South Dakota Investment Council acquired a new stake in Enhabit in the 3rd quarter valued at $45,000. 95.55% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research analysts have commented on the company. Stifel Nicolaus boosted their price objective on Enhabit from $17.00 to $18.00 in a research note on Wednesday, February 15th. Citigroup increased their price objective on shares of Enhabit from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Friday, February 17th. Credit Suisse Group reissued a “neutral” rating and set a $15.00 target price on shares of Enhabit in a research report on Thursday, February 16th. UBS Group initiated coverage on shares of Enhabit in a report on Thursday, December 8th. They set a “sell” rating and a $12.00 price target for the company. Finally, CJS Securities initiated coverage on shares of Enhabit in a report on Tuesday, December 13th. They issued a “market perform” rating and a $18.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Enhabit presently has a consensus rating of “Hold” and a consensus price target of $16.71.
Enhabit Price Performance
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
- Get a free copy of the StockNews.com research report on Enhabit (EHAB)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.